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Abstract
Background: This study aimed to determine the association of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in
circulation and peripheral blood mononuclear cells (PBMCs) with inflammatory and oxidative stress markers in nonobese
women and according to menopausal status. Lp-PLA2 activity, a marker for cardiovascular risk is associated with
inflammation and oxidative stress.
Methodology/Principal Findings: Eighty postmenopausal women (53.064.05 yr) and 96 premenopausal women
(39.769.25 yr) participated in this study. Lp-PLA2 activities, interleukin (IL)-6, tumor necrosis factor (TNF)-a, and IL-1b in
plasma as well as in PBMCs were measured. Plasma ox-LDL was also measured. Postmenopausal women demonstrated
higher circulating levels of ox-LDL and IL-6, as well as IL-6, TNF-a, and IL-1b in PBMCs, than premenopausal women. In both
groups, plasma Lp-PLA2 activity positively correlated with Lp-PLA2 activity in PBMCs and plasma ox-LDL. In premenopausal
women, Lp-PLA2 activities in plasma and PBMCs positively correlated with IL-6, TNF-a, and IL-1b in PBMCs. In
postmenopausal women, plasma ox-LDL positively correlated with PBMC cytokine production. In subgroup analysis of
postmenopausal women according to plasma ox-LDL level (median level: 48.715 U/L), a significant increase in Lp-PLA2
activity in the plasma but not the PBMCs was found in the high ox-LDL subgroup. Plasma Lp-PLA2 activity positively
correlated with unstimulated PBMC Lp-PLA2 activity in the low ox-LDL subgroup (r = 0.627, P,0.001), whereas in the high
ox-LDL circulating Lp-PLA2 activity positively correlated with plasma ox-LDL (r = 0.390, P = 0.014) but not with Lp-PLA2
activity in PBMCs.
Conclusions/Significance: The lack of relation between circulating Lp-PLA2 activity and Lp-PLA2 activity in PBMCs was
found in postmenopausal women with high ox-LDL. This may indicate other sources of circulating Lp-PLA2 activity except
PBMC in postmenopausal women with high ox-LDL. We also demonstrated that circulating Lp-PLA2 and PBMC secreted Lp-
PLA2 associate differently with markers of oxidative stress and sub clinical inflammation in nonobese women, particularly
according to the menopausal states.
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Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known
as plasma platelet activating factor acetylhydrolase (PAF-AH), is
unique among members of the phospholipase A2 superfamily due to
its origin, its association with circulating lipoproteins, and its
substrate preference for polar phospholipids, including those
generated during the oxidation of low-density lipoprotein (LDL)
[1]. Lp-PLA2 is secreted by monocytes, macrophages, T lympho-
cytes, and mast cells [2], and catalyzes the hydrolysis of oxidized
LDL (ox-LDL) [3], which produces the proinflammatory mediators
lysophosphatidylcholine and oxidized fatty acid [3]. There has been
a growing interest in Lp-PLA2 because of its key role in lipid
metabolism and in initiating inflammation [4]. Epidemiological and
clinical studies have indicated that Lp-PLA2 is a marker for
cardiovascular risk, with higher plasma Lp-PLA2 mass or activity
correlating with a higher risk for cardiovascular events independent
of systemic inflammation and other conventional risk factors [5–11].
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Many studies found correlations between Lp-PLA2 and
triglycerides, LDL-cholesterol, high-density lipoprotein (HDL)-
cholesterol, body mass index (BMI), age, sex, use of postmeno-
pausal hormones, and smoking [6,9,12–19]. Lp-PLA2 has been
associated with an increased incidence of ischemic stroke among
nonusers of hormone therapy in postmenopausal women indepen-
dent of traditional cardiovascular risk factors. Furthermore, Keyzer
et al. [20] found a positive association between Lp-PLA2 activity
and inflammation and oxidative stress in a hypercholesterolemic
swine model for atherosclerosis. Wang et al. [21] reported the
stimulatory effect of ox-LDL on the expression of Lp-PLA2 in
monocytes, which are a primary source of this enzyme. These
recent findings in animal and in vitro studies may provide insight
into the interaction between Lp-PLA2 activity and oxidative stress
in the context of atherosclerosis. Therefore, our aim was to study
the relationship of Lp-PLA2 activity in plasma and the enzyme
activity in supernatants from nonstimulated peripheral blood
mononuclear cell (PBMC) cultures. Plasma ox-LDL and cytokine
production from PBMCs in healthy nonobese women and also
according to the menopausal status were evaluated.
Methods
Study participants
A total of 176 healthy, nonobese women aged 20–68 years were
recruited during routine check-ups at a health promotion center at
Yonsei University Hospital. Postmenopausal status (n = 80) was
defined as an absence of menstruation for at least 12 months and
the presence of estrogen deficiency symptoms, including hot
flushes, increased sweating, nervousness, irritability, depression,
palpitations, insomnia, headaches, dyspareunia, and joint pains.
Premenopausal status (n = 96) was defined as the presence of
regular menses. At the time of subject enrollment, subjects were
interviewed about smoking status (non-/ex-smoker and current
smoker), and frequency of alcohol intake. Alcohol consumption
was calculated as the grams of ethanol ingested per day and
cigarettes smoking data were reported as the number of cigarettes
smoked per day. All participants were clinically healthy and were
not taking any medications known to affect the immune system,
such as oral contraceptives, lipid-lowering agents, anti-hyperten-
sive drugs, functional foods, or vitamin and/or mineral supple-
ments. The purpose of the study was carefully explained to all
participants and their written consent was obtained prior to their
participation. The study design was approved by the Institutional
Review Board of Yonsei University.
Anthropometric parameters, blood pressure, and blood
collection
Body weight and height were measured in the morning, lightly
clothed without shoes and the BMI was calculated as body weight
in kilograms divided by height in meters squared. Waist
circumference was measured at the umbilical level with the
subjects standing after normal expiration and the hip girth was
measured at the widest part of the hip and, the waist and hip ratio
(WHR) was calculated.
Blood pressure (BP) was measured in the left arm of seated
patients with an automatic blood pressure monitor (TM-2654,
A&D, Tokyo, Japan) after a 20-min rest. After a 12-hour fast,
venous blood specimens were collected in EDTA-treated or
untreated tubes. The blood specimens collected in the EDTA-
treated tubes were used for the isolation of PBMCs or separated
into plasma and stored at 270uC until further analysis. The blood
samples collected in non-treated tubes were separated into serum
and stored until further analysis.
Serum lipid profile, fasting glucose, free fatty acid, and
white blood cell count
Fasting total-cholesterol and triglyceride levels were measured
using commercially available kits on a Hitachi 7150 Autoanalyzer
(Hitachi Ltd., Tokyo, Japan). After precipitation of serum
chylomicrons with dextran sulfate magnesium, the concentrations
of LDL- and HDL-cholesterol in the supernatants were enzymat-
ically measured. Fasting glucose levels were measured using a
glucose oxidase method with a Beckman Glucose Analyzer
(Beckman Instruments, Irvine, CA, USA). Free fatty acids were
analyzed with a Hitachi 7150 autoanalyzer (Hitachi Ltd, Tokyo,
Japan).White blood cell (WBC) count was determined using the
HORIBA ABX diagnostic (HORIBA ABX SAS, Parc Euro-
medicine, France).
Cytokine secretion in non-stimulated PBMCs
Whole blood was mixed with the same volume of RPMI 1640
(Gibco, Invitrogen, Carlsbad, CA, USA) and gently laid on a
histopaque-1077 (Sigma-Aldrich, St. Louis, MO, USA). The
sample was then centrifuged at 2000 rpm for 20 min at 10uC.
After the separation, a thin layer of PBMCs was isolated and
washed twice with RPMI 1640. The pellet was resuspended in
RPMI 1640 with streptomycin. Isolated PBMCs were cultured in
RPMI 1640 supplemented with 10% fetal bovine serum, seeded in
12-well plates (16106 cells/mL; Nunc, Roskilde, Denmark), and
incubated at 37uC with 5% CO2 for 24 hours. After a 24-hour
incubation, supernatants were collected and stored at 280uC until
interleukin (IL)-1b, IL-6, tumor necrosis factor (TNF)-a, and Lp-
PLA2 activity levels were assayed [22,23].
Cytokine assay for IL-1b, IL-6, and TNF-a levels in serum
and PBMC supernatants
Levels of IL-1b, IL-6, and TNF-a in serum and PBMC
supernatants were measured using the Bio-PlexTM Reagent Kit on
the Bio-PlexTM (Bio-Rad Laboratories, Hercules, CA, USA),
according to the manufacturer’s instructions.
Lp-PLA2 activity in plasma and PBMC supernatants
Lp-PLA2 activity in plasma and PBMC supernatants was
measured by using a modification of a previously described high-
throughput radiometric activity assay [11].
Plasma-oxidized LDL and serum high sensitivity-C-
reactive protein (hs-CRP)
Plasma ox-LDL was measured using an enzyme immunoassay
(Mercodia, Uppsala, Sweden). The resulting color reaction was
read at 450 nm with a Wallac Victor2 multilabel counter (Perkin
Elmer Life Sciences, Turku, Finland). Serum hs-c-reactive protein
(CRP) levels were measured with an Express PlusTM auto-analyzer
(Chiron Diagnostics Co., Walpole, MA, USA) using a commer-
cially available, high-sensitivity CRP-Latex(II) 62 kit (Seiken
Laboratories Ltd., Tokyo, Japan).
Urinary 8-epi-prostaglandin F2a (8-epi-PGF2a) levels
Urine was collected in polyethylene bottles containing 1%
butylated hydroxytoluene after a 12-hour fast. The bottles were
immediately covered with aluminum foil and stored at 270uC
until further analysis. The compound 8-epi-PGF2a was measured
using an enzyme immunoassay (BIOXYTECH urinary 8-epi-
PGF2a
TM Assay kit, OXIS International Inc., Portland, OR,
USA). Urinary creatinine levels were determined using the alkaline
picrate (Jaffe) reaction. Urinary 8-epi-PGF2a levels are expressed
as pmol/mmol creatinine.
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Serum follicle stimulating hormone (FSH) and 17ß-
estradiol levels
Serum levels of FSH and 17ß-estradiol were measured using
commercially-available kits (ADIVIA Centaur FSH and ADIVIA
Centaur Estradiol, respectively, Siemens, USA) on the ADIVIA
Centaur (ADIVIA Centur, Siemens).
Data analysis
Statistical analyses were performed using SPSS version 12.0
for Windows (SPSS Inc., Chicago, IL, USA). The independent t-
test was used to compare parameters between the two groups.
One-way analysis of variance (ANOVA) with Bonferroni
correction was used to test whether there were effects from
menopausal state and plasma ox-LDL levels (below or above the
median level) in postmenopausal women. General linear model
(GLM) analysis was also performed with adjustment for age or
BMI and alcohol consumption. Frequency was tested with the
chi-square test. Pearson and partial correlation coefficients were
used to examine relationships between variables. For descriptive
purposes, mean values are presented using untransformed
values. Results are expressed as the mean 6 standard deviation
(SD). A two-tailed value of P,0.05 was considered statistically
significant.
Results
Clinical characteristics of study participants
In this study, postmenopausal women had a significantly higher
BMI and included a lower percentage of alcohol drinkers (Table 1).
Before and after adjusting for age, BMI and percentage of alcohol
drinkers, postmenopausal women demonstrated significantly
higher WHRs in addition to higher serum levels of total-
cholesterol, LDL-cholesterol, and glucose, and lower serum levels
of hs-CRP, than premenopausal women. Postmenopausal women
also had significantly lower serum levels of 17b-estradiol and
higher FSH levels than premenopausal women. These differences
confirmed that postmenopausal women had estrogen deficiency.
Premenopausal and postmenopausal women did not differ in
terms of diastolic BP, or serum levels of triglycerides, HDL-
cholesterol, and free fatty acid. Premenopausal and postmeno-
pausal women also did not differ in terms of the number of
circulating leukocytes (Table 1).
Oxidative stress markers, cytokines, and Lp-PLA2 activity
according to menopausal status
Table 2 provides data for oxidative stress markers, circulating
levels of cytokines, and Lp-PLA2 activity in the plasma and in
supernatants from non-stimulated PBMC cultures from premen-
opausal and postmenopausal women. Significant differences
between the two groups are indicated in the last column before
and after adjustment for age, BMI and percentage of alcohol
drinkers. Plasma ox-LDL and serum IL-6 levels in the
postmenopausal group were significantly higher than those in
premenopausal women. Urinary levels of 8-epi-PGF2a, serum
levels of TNF-a and IL-1b, and Lp-PLA2 activities in plasma and
cultured nonstimulated PBMC supernatants did not significantly
differ between the two groups. Additionally, plasma Lp-PLA2
activity was not significantly difference between the two groups
after further adjustment for LDL-cholesterol (p = 0.746). Non-
stimulated PBMCs from postmenopausal women secreted
significantly higher amounts of IL-6, TNF-a, and IL-1b into
the culture media than those from premenopausal women
(Table 2).
Correlations among oxidative stress markers, cytokines,
and Lp-PLA2 activity in the circulation and in PBMCs
according to menopausal status
In both premenopausal and postmenopausal women, plasma
Lp-PLA2 activity positively correlated with plasma ox-LDL and
supernatant Lp-PLA2 activity from nonstimulated PBMC
cultures (Table 3). In premenopausal women, Lp-PLA2 activity
in plasma and PBMC supernatants positively correlated with IL-
6, TNF-a, and IL-1b levels in nonstimulated PBMCs. After the
adjustment for age, BMI, alcohol consumption, the relationships
were still retained (IL-6 and IL-1b). In postmenopausal women,
plasma ox-LDL positively correlated with IL-6, TNF-a, and IL-
1b levels in cultured nonstimulated PBMC supernatants. After
the adjustment, the relationships were still retained (TNF-a and
IL-1b) (Table 3). IL-6, TNF-a, and IL-1b levels in nonstimu-
lated PBMCs were linearly interrelated for both premenopausal
and postmenopausal women (data not shown). In the postmen-
opausal women, serum IL-6 levels positively correlated with
serum IL-1b (r = 0.396, P,0.001) and serum TNF-a (r = 0.296,
P = 0.012). Serum IL-6 levels negatively correlated with PBMC
levels of IL-6 (r =20.299, P = 0.005), TNF-a (r =20.359,
P = 0.001), and IL-1b (r =20.302, P = 0.005) in premenopausal
women, whereas serum IL-6 levels positively correlated with
PBMC levels of IL-6 (r = 0.317, P = 0.006), TNF-a (r = 0.313,
P = 0.007), and IL-1b (r = 0.316, P = 0.006) in postmenopausal
women.
Lp-PLA2 activity, oxidative stress markers, and
LDL-cholesterol according to menopausal status and
plasma ox-LDL levels
Since Lp-PLA2 is known to hydrolyze the sn2 ester bond of
oxidized phospholipids including ox-LDL [12], the postmeno-
pausal women were subdivided into two groups according to
plasma ox-LDL level: high ox-LDL ($48.715 U/L, n= 40) and
low ox-LDL (,48.715 U/L, n= 40) according to the median
level of ox-LDL. In the postmenopausal women with low ox-
LDL, plasma Lp-PLA2 activity positively correlated with
unstimulated PBMC Lp-PLA2 activity (r0 = 0.627, P0,0.001;
r1 = 0.597, P1,0.001) before and after the adjustment for age,
BMI, and alcohol consumption (Fig. 1). In postmenopausal
women with high ox-LDL, however, circulating Lp-PLA2 activity
positively correlated with plasma ox-LDL (r0 = 0.390, P0 = 0.014;
r1 = 0.443, P1 = 0.007) but not with Lp-PLA2 activity in PBMCs.
Additionally partial correlation coefficient with adjust for age,
BMI, alcohol consumption, and LDL-cholesterol level were also
used to examine the relationships between variables. In the
postmenopausal women with low ox-LDL, plasma Lp-PLA2
activity positively correlated with non-stimulated PBMC Lp-
PLA2 activity (r2 = 0.526, P2 = 0.002) but not correlated with
plasma ox-LDL (r2 = 0.098, P2 = 0.586). In postmenopausal
women with high ox-LDL, the positive correlation between
circulating Lp-PLA2 activity and plasma ox-LDL (r2 = 0.295,
P2 = 0.085) was a little bit attenuated, but is in a positive
direction. On the other hand, circulating Lp-PLA2 did not
correlation with Lp-PLA2 activity in PBMCs (r2 =20.052,
P2 = 0.777). The postmenopausal group with high ox-LDL had
higher levels of plasma Lp-PLA2 activity, urinary 8-epi-PGF2a
excretion, and serum LDL-cholesterol than the postmenopausal
group with low ox-LDL, or the premenopausal group, before and
after adjustment for age or BMI and percentage of alcohol
drinkers (Fig. 2). In addition, the postmenopausal group with low
ox-LDL had higher serum levels of LDL-cholesterol than the
premenopausal group.
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Discussion
The major finding of this study is the lack of relation between
circulating Lp-PLA2 activity and Lp-PLA2 activity in PBMCs in
postmenopausal women with high ox-LDL ($48.715 U/L, above
median). A significant increase in Lp-PLA2 activity in the plasma
but not the PBMCs of postmenopausal women with high ox-LDL
may indicate other sources of Lp-PLA2 production except
PBMC. The extent of the increase in plasma Lp-PLA2 may
depend not only on the levels of lipoproteins carrying Lp-PLA2 in
circulation but also on the cellular synthesis of this enzyme [24].
Monocytes, macrophages, T-lymphocytes, mast cells, and liver
cells are known as the main sources of Lp-PLA2 [25,26].
Recently, Keyzer et al. [20] found increased circulating Lp-
PLA2 activity with increased ox-LDL levels in hypercholesterol-
emic pigs and the main source of increased circulating Lp-PLA2
activity were plaque macrophages [20,27,28]. Therefore, the Lp-
PLA2 production in plaque macrophages could partly explain the
positive correlation of circulating Lp-PLA2 activity with plasma
ox-LDL but not with Lp-PLA2 activity in PBMCs from
postmenopausal women with high ox-LDL in this study.
However, we could not measure Lp-PLA2 activity in plaque
macrophages, or the plaque or intima itself, where it may be of
most biological relevance.
Table 1. Clinical characteristics of the study participants according to menopausal status.
Premenopausal women (n=96) Postmenopausal women (n=80) P0 P1
Age (yr) 39.7 6 9.25 53.0 6 4.05 ,0.001 -
Years since menopause - 3.49 6 3.87 - -
Body Mass Index (kg/m2) 21.9 6 2.84 22.8 6 2.27 0.024 -
Cigarette smoker, n (%) 1 (1.0) 2 (2.5) 0.592 -
Alcohol drinker, n (%) 62 (64.6) 37 (46.3) 0.022 -
Waist hip ratio 0.84 6 0.05 0.88 6 0.05 ,0.001 0.042
Systolic BP (mmHg) 109.3 6 14.2 118.6 6 12.0 ,0.001 0.614
Diastolic BP (mmHg) 74.2 6 10.6 76.0 6 8.75 0.238 0.592
Triglyceride (mg/dL)$ 90.7 6 41.6 98.2 6 45.4 0.489 0.340
Total-cholesterol (mg/dL) 182.6 6 26.4 210.3 6 32.7 ,0.001 0.004
LDL-cholesterol (mg/dL) 109.1 6 23.4 132.5 6 28.6 ,0.001 0.006
HDL-cholesterol (mg/dL) 55.4 6 12.8 58.1 6 14.1 0.185 0.145
Glucose (mg/dL)$ 85.5 6 7.98 92.1 6 12.3 ,0.001 0.016
Free fatty acid (uEq/L)$ 407.1 6 191.8 409.5 6 158.2 0.488 0.548
hs-CRP (mg/dL)$ 0.51 6 0.75 0.36 6 0.92 ,0.001 ,0.001
Serum FSH (IU/L) 10.6 6 17.9 75.2 6 28.9 ,0.001 ,0.001
Serum 17ß-estradiol (pg/mL)$ 134.6 6 126.9 18.2 6 24.8 ,0.001 ,0.001
White blood cells (6109/L)$ 4.94 6 1.01 4.98 6 1.15 0.785 0.948
Means 6 SD. Tested by independent t-test or general linear model with the adjustment.
$tested by log-transformed P0: unadjusted, P1: adjusted for age, BMI, and alcohol consumption.
doi:10.1371/journal.pone.0029675.t001
Table 2. Oxidative stress markers, cytokines, and Lp-PLA2 activity according to menopausal status.
Premenopausal women (n=96) Postmenopausal women (n=80) P0 P1
Plasma oxidized LDL(U/L)$ 40.9 6 11.4 56.7 6 23.8 ,0.001 0.031
Urinary 8-epi-PGF2a (pg/mg creatinine)
$ 1079.1 6 281.6 1199.8 6 461.5 0.179 0.400
Serum IL-6 (pg/mL)$ 1.94 6 1.28 4.53 6 5.27 ,0.001 0.005
Serum TNF-a (pg/mL)$ 5.88 6 7.03 6.64 6 10.6 0.795 0.213
Serum IL-1ß (pg/mL)$ 0.70 6 1.17 0.77 6 1.53 0.929 0.961
Lp-PLA2 activity (nmol/mL/min) 28.3 6 9.42 30.6 6 7.77 0.084 0.447
Nonstimulated PBMC
IL-6 (pg/mL)$ 786.1 6 3107.9 1409.0 6 6504.8 ,0.001 0.027
TNF-a (pg/mL)$ 169.3 6 803.4 626.9 6 2044.3 ,0.001 0.008
IL-1ß (pg/mL)$ 14.4 6 42.4 119.7 6 351.2 ,0.001 ,0.001
Lp-PLA2 activity (nmol/mL/min) 2.01 6 0.55 2.11 6 0.61 0.265 0.621
Mean 6 SD. Tested by independent t-test or general linear model with the adjustment.
$tested by log-transformed. P0: unadjusted, P1: adjusted for age, BMI and alcohol consumption.
doi:10.1371/journal.pone.0029675.t002
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Table 3. Correlations among oxidative stress markers, cytokines, and Lp-PLA2 activity in the circulation and in PBMCs according to
menopausal status.
Premenopausal women (n=96) Postmenopausal women (n=80)
Plasma
ox-LDL
Plasma Lp-PLA2
activity
Nonstimulated
PBMC Lp-PLA2 Plasma ox-LDL
Plasma Lp-PLA2
activity
Nonstimulated
PBMC Lp-PLA2
r0 r1 r0 r1 r0 r1 r0 r1 r0 r1 r0 r1
Plasma ox- LDL(U/L)$ - - 0.244* 0.247* 0.022 0.006 - - 0.390*** 0.394** 0.215 0.154
Serum IL-6 (pg/mL)$ 0.042 0.051 20.150 20.154 20.020 20.032 0.171 0.143 0.022 0.016 0.019 20.017
Serum TNF-a (pg/mL)$ 20.037 20.016 20.178 20.202 0.101 0.068 0.090 0.031 20.022 20.018 0.030 20.008
Serum IL-1ß (pg/mL)$ 20.018 20.020 0.042 0.033 0.073 0.042 20.061 20.062 20.050 20.046 20.022 20.048
Lp-PLA2 activity (nmol/
mL/min)
0.244* 0.247* - - 0.427*** 0.422*** 0.390*** 0.394** - - 0.380** 0.374**
Nonstimulated PBMCs
IL-6 (pg/mL)$ 0.058 0.042 0.326** 0.318** 0.363*** 0.353** 0.230* 0.222 0.051 0.073 0.127 0.121
TNF-a (pg/mL)$ 0.106 0.072 0.209* 0.202 0.205* 0.198 0.308** 0.307** 0.171 0.208 0.032 0.022
IL-1ß (pg/mL)$ 0.056 0.035 0.277** 0.269** 0.272** 0.255* 0.304** 0.301** 0.220 0.251* 0.080 0.067
Lp-PLA2 activity (nmol/
mL/min)
0.022 0.006 0.427*** 0.422*** - - 0.215 0.154 0.380** 0.374** - -
Pearson and partial correlation analysis, r0: unadjusted, r1: adjusted for age, BMI, and alcohol consumption,
*P,0.05,
**P,0.01,
***P,0.001,
$tested by log-transformed.
doi:10.1371/journal.pone.0029675.t003
Figure 1. Relationship between Lp-PLA2 activity from PBMCs or plasma ox-LDL and plasma Lp-PLA2 activity according to plasma
ox-LDL (below or above the median level of 48.715 U/L) in postmenopausal women. 1tested by log-transformed. Tested by Pearson
correlation (r0) or partial correlation analysis (r1, r2). r0: correlation coefficient, unadjusted. r1: correlation coefficient after adjusted for age, BMI, and
alcohol consumption. r2: correlation coefficient after adjusted for age, BMI, alcohol consumption, and LDL-cholesterol.
doi:10.1371/journal.pone.0029675.g001
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Lp-PLA2 is thought to play an atherogenic role by hydrolyzing
oxidized phospholipids in ox-LDL, resulting in the generation of
two bioactive lipid mediators, lysophosphatidyl choline, and
oxidized free fatty acids [3,24,29]. The biological role of Lp-
PLA2 is also controversial; initial reports indicated an antiathero-
genic effect, whereas growing evidence has demonstrated a role for
Lp-PLA2 as a proinflammatory molecule and an independent risk
factor for CVD [5,11,14,30,31]. Lp-PLA2 belongs to the
expanding superfamily of structurally diverse phospholipase A2
enzymes, also known as PAF-AH [32]. It travels mainly with LDL
in the blood, and less than 20% is associated with HDL [1]. In
mice, the majority of plasma PAF-AH is bound to HDL, this was
considered as possible antiatherogenic effect [33]. In human
atherosclerotic lesions, two main sources of Lp-PLA2 were
identified in human atherosclerotic lesions, including that which
is brought into the intima bound to LDL from the circulation, and
that which is synthesized de novo by plaque inflammatory cells (i.e.
macrophages, T cells, mast cells) [1,32,34]. Lp-PLA2 hydrolyzes
the sn-2 ester bond of oxidized phospholipids, generating bioactive
oxidized free fatty acids and lysophosphatidyl choline, which are
potent proinflammatory and proatherogenic products [1]. Indeed,
Stafforini et al. [35] showed that the secreted form of Lp-PLA2
released F2-isoprostanes, the end-products of lipid oxidation, from
the sn-2 position of phosphatidylcholine with high affinity. Kono
et al. [36] reported that intracellular type II Lp-PLA2, which
shares homology with the plasma enzyme Lp-PLA2, is involved in
the metabolism of esterified 8-iso-PGF2a. We also showed that
mean levels of plasma Lp-PLA2 activity and urinary 8-epi-PGF2a
were higher among postmenopausal women with high ox-LDL
than those with low ox-LDL or in premenopausal women.
Ox-LDL stimulates Lp-PLA2 expression in monocytes through
the pathway of phosphatidylinositol 3-kinase and p38 mitogen-
activating protein kinase [21], which mediates the expression of
many genes involved in stress-induced responses (e.g., IL-1b) [37].
Shi et al. [24] found that the activation of leukocytes in the
experimental model of diabetes and hypercholesterolemia is
associated with a rapid increase in circulating Lp-PLA2 and an
upregulation in a range of inflammatory mediators, including IL-
6, TNF-a, and IL-1b. In the postmenopausal women in this study,
plasma ox-LDL also positively correlated with IL-6, TNF-a, and
IL-1b levels in cultured, nonstimulated PBMC supernatants. This
observation supports the previous finding that the presence of ox-
LDL significantly induced the expression of IL-1b, IL-6, and
TNF-a, whereas unmodified LDL had no effect on the expression
of inflammatory mediators [24]. This correlation, however, was
not found in premenopausal women. Additionally, the postmen-
opausal women showed higher levels of plasma ox-LDL and
serum IL-6, and more cytokine production from PBMCs than the
premenopausal women. This result may be partly related to the
exaggerated production of cytokines caused by estrogen depriva-
tion after menopause. Rachon et al. [22] showed that estrogen
deprivation after menopause enhanced IL-6 production by
PBMCs and increased serum IL-6 levels in postmenopausal
women. It has been also suggested that the increased production of
cytokines in healthy, older individuals results from the loss of sex
steroids [38]. Estradiol acts to inhibit pro-inflammatory cytokine
gene expression, NF-kB binding, and production of proinflamma-
tory cytokines [39,40]. In addition, the levels of IL-6, TNF-a, and
IL-1b in supernatants from nonstimulated PBMC cultures of the
postmenopausal women positively correlated with serum IL-6
levels [41]. This finding supports the previous suggestion that
locally-produced TNF-a and IL-1b do not escape into the
circulation, although they induce a strong systemic IL-6 response
[41]. Therefore, enhanced cytokine production by PBMCs in
postmenopausal women, may not only result from the activation of
leukocytes in the presence of high ox-LDL after menopause but
Figure 2. Lp-PLA2 activity in plasma and supernatants from nonstimulated PBMC cultures and oxidative stress markers according
to menopausal status and plasma ox-LDL levels (below or above the median level of 48.715 U/L). Data are means 6 SD. 1tested by log-
transformed. P0: unadjusted, tested by one-way ANOVA with Bonferroni method P1: adjusted for BMI and alcohol consumption, tested by general
linear model (GLM) analysis. P2: adjusted for age, BMI, and alcohol consumption, tested by GLM analysis.
doi:10.1371/journal.pone.0029675.g002
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also may be the consequence of the decrease in estrogen levels or
other factors that contribute to the aging process [12,22,39]. On
the other hand, cytokine production particularly IL-6 and IL-1b
from PBMCs in premenopausal women, but not in postmeno-
pausal women positively correlated with Lp-PLA2 activity in
plasma and PBMC supernatants. The biological role of Lp-PLA2
or the activity levels according to the menopausal states are still
controversial, but our results may be partly explained by the recent
studies demonstrating that Lp-PLA2 works as an proinflammatory
molecules or initiate inflammatory response, and is an indepen-
dent risk factor for CVD [5,11,14,30,31]. It is known that
circulating Lp-PLA2 activity is derived from atherosclerotic plaque
cells, however our study subjects had not carried cardiovascular
disease including atherosclerosis or other chronic diseases (i.e.
diabetes, or dyslipidemia). Therefore, we could observe the clear
positive correlation in premenopausal women rather than
postmenopausal women whose metabolisms are interfered by the
stressful condition (i.e. oxidative stress, estrogen deprivation).
In addition, the prospective observation needs to be performed
in the future to investigate if Lp-PLA2 is a physiological responder
or an inducer of vascular inflammation. Actually, the Lp-PLA2
activity may be different according to the ethnicities, for example,
rare homozygous mutation of Lp-PLA2 V279F polymorphism, the
F/F genotype indicating the loss of function of Lp-PLA2 activity
and the less atherogenic properties is found in Korean but not in
Western people [42]. Our study was designed for the cross-
sectional observation, not for prospective observation, thus it is not
easy to determine the casual relationship between Lp-PLA2 and
inflammatory response. In summary, the lack of relationship
between circulating Lp-PLA2 activity and Lp-PLA2 activity in
PBMCs was found in postmenopausal women with high ox-LDL.
This may indicate other sources of circulating Lp-PLA2 activity
except PBMC in postmenopausal women with high ox-LDL. We
also demonstrated that circulating Lp-PLA2 and PBMC secreted
Lp-PLA2 associate differently with markers of oxidative stress and
sub clinical inflammation in nonobese women, particularly
according to the menopausal states.
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